DOI: http://dx.doi.org/10.18203/issn.2454-2156.IntJSciRep20212834

Prevalence of metabolic syndrome in type 2 diabetic patients

Tina Uprety, Saroj Kunwar, Ashim Rai, Avaya Khanal, Shraddha Thapa, Soumya Harsha Gurung, Sanjita Shrestha, Prakirti Karmacharya, Govinda Akela Poudel

Abstract


Background: Metabolic syndrome (MetS) and diabetes mellitus concurrently potentiates a number of risk factors, significantly higher prevalence of cardiovascular diseases. Numerous risk factors associated with diabetes gets intensified by the presence of metabolic syndrome. Diabetes and metabolic syndrome together can increase the risk of cardiovascular disease by 2 to 4 folds. The main objective of this study was to determine the prevalence of MetS in type 2 diabetic mellitus (T2DM) patients. Components of metabolic syndrome were measured and compared to determine the prevalence.

Methods: Hospital based cross-sectional study was conducted from September 2019 to December 2019 at star hospital and modern technical college, Sanepa, Nepal. A total number of 353 patients with T2DM visiting star hospital were included in the study.

Results: Among 353 participants, MetS was diagnosed in 242 (68.5%) participants using NCEP-ATP III criteria. The prevalence of MetS was 68.5% among which male were 123 (76.3%) and female were 119 (61.9%). MetS was found to be highest in age group of 50-59 years with 34.2% (83) participants. Dyslipidemia with raised TG (triglyceride) 71.4% and reduced HDL 76% was found to be most prevalent component in our study followed by hypertension 73.1%.

Conclusions: 68.5% prevalence of MetS in T2DM with 76.3% male and 61.9% female according to NCEP-ATP III was found with anthropometric indices significantly higher in the male population compared to female population.


Keywords


Diabetes mellitus, Metabolic syndrome, Dyslipidemia, Hypertension

Full Text:

PDF

References


Kaul K, Tarr JM, Ahmad SI, Kohner EM, Chibber R. Introduction to diabetes mellitus. In: Ahmad SI, eds. Diabetes: Advances in Experimental Medicine and Biology. New York, NY: Springer; 2013: 1-11.

Bharathkumar H, Sundaram MS, Jagadish S, Paricharak S, Hemshekhar M, Mason D, et al. Novel benzoxazine-based aglycones block glucose uptake in vivo by inhibiting glycosidases. PloS One. 2014;9(7):102759.

Harvery RA, Champe PC. Lippincott's Illustrated Review: Biochemistry. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2004.

Mayo clinic. Fact sheet: Metabolic syndrome. Available at: https://www.mayoclinic.org/diseases-conditions/metabolic-syndrome/symptoms-causes/syc-20351916. Accessed on 29 May 2021.

Ferrannini E. Physiological and metabolic sequences of obesity. Metabolism. 1995;44:15-7.

Islam SMS, Purnat TD, Phuong NTA, Mwingira U, Schacht K, Fröschl G. Non-communicable diseases (NCDs) in developing countries: a symposium report. Glob Health. 2014;10:81.

Birarra MK, Gelayee DA. Metabolic syndrome among type 2 diabetic patients in Ethiopia: a cross-sectional study. BMC Cardiovasc Disord. 2018;18(1):149.

Osei-Yeboah J, Owiredu WK, Norgbe GK, Lokpo SY, Gyamfi J, Allotey EA, et al. The prevalence of metabolic syndrome and its components among people with type 2 diabetes in the municipality, Ghana: a cross-sectional study. International journal of chronic diseases. 2017;2017:8765804.

WHO. Fact sheet: Waist circumference and waist-hip ratio: report of a WHO expert consultation, 2008. Available at: https://www.who.int/ nutrition/publications/obesity/WHO_report_waistcircumference_and_waisthip_ratio/en/. Accessed on 29 May 2021.

Tamang HK, Timilsina U, Thapa S, Singh KP, Shrestha S, Singh P, et al. Prevalence of metabolic syndrome among Nepalese type 2 diabetic patients. Nepal Med Coll J. 2013;15(1):50-5.

Bhattarai S, Kohli SC, Sapkota S. Prevalence of metabolic syndrome in type 2 diabetes mellitus patients using NCEP/ATP III and IDF criteria in Nepal. Nepal J Med Sci. 2012;1(2):79-83.

Pokharel DR, Khadka D, Sigdel M, Yadav NK, Acharya S, Kafle RC, et al. Prevalence of metabolic syndrome in Nepalese type 2 diabetic patients according to WHO, NCEP ATP III, IDF and harmonized criteria. J Diabet Metabol Disord. 2014;13(1):104.

Shakya D, Vijay KC. Prevalence of metabolic syndrome in patients with type 2 diabetes mellitus in a tertiary care hospital. Med J Shree Birendra Hospit. 2019;18(2):36-41.

Yadav D, Mahajan S, Subramanian SK, Bisen PS, Chung CH, Prasad GB. Prevalence of metabolic syndrome in type 2 diabetes mellitus using NCEP-ATPIII, IDF and WHO definition and its agreement in Gwalior Chambal region of Central India. Global J Health Sci. 2013;5(6):142-55.